Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Genentech

Most Recent Events

  • 06 Oct 2020 Status changed from active, no longer recruiting to completed.
  • 28 Jul 2020 Results (data cut off: 23 april 2018; n=20) assessing safety and efficacy of atezolizumab plus bevacizumab in patients with platinum-resistant ovarian cancer cohort published in the Clinical Cancer Research
  • 11 Feb 2020 Planned End Date changed from 16 Jan 2020 to 29 Feb 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top